Kornimate/medical-research-clean huggingface dataset:
topical use of 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone (a-007) in the treatment of advanced malignancies including kaposi's sarcoma and lymphoproliferative disorders

Conditions: Sarcoma, Kaposi; HIV Infections; Lymphoproliferative Disorders

Summary: to evaluate topical a-007 in patients with advanced malignancies including kaposi's sarcoma and lymphoproliferative disorders.


Eligibility criteria:
inclusion criteria concurrent medication: allowed: * maintenance antihormones, hormones, and glucocorticoids. patients must have: * histologically proven metastatic cancer including kaposi's sarcoma and lymphoproliferative disorders to the skin or cutaneous sites. note: * primary basal or squamous cell cancer of the skin is allowed. * failed both primary and secondary chemotherapy and/or immunotherapy protocols. * measurable skin or cutaneous lesions. 4 life expectancy of at least 20 weeks. prior medication: required: * prior therapy for cutaneous lesions from kaposi's sarcoma or lymphoproliferative disorders. allowed: * prior maintenance steroids and hormone/antihormone therapy. exclusion criteria co-existing condition: patients with the following symptoms or conditions are excluded: * active infections other than medically stable hiv infection. * active congestive heart failure, any persistent arrhythmia or transient serious arrhythmia (ventricular tachycardia, sinoatrial arrest, etc.), or progressive cardiomyopathy. * unstable blood pressure. * seizures or other cns disorders. * severe unstable diabetes mellitus. * coagulopathies. * thrombotic disease. * any other medical conditions that would prevent completion of study or produce significant risk to patient. concurrent medication: excluded: * concomitant chemotherapy or immunotherapy. * ongoing corticosteroid therapy (unless maintenance). patients with the following prior conditions are excluded: * history of active cardiopulmonary or respiratory disease. * history of sun hypersensitivity and photosensitive dermatoses. * history of allergy or hypersensitivity to cosmetics, toiletries, or other dermatological products.

Keywords: skin neoplasms sarcoma, kaposi acquired immunodeficiency syndrome antineoplastic agents
evaluation of serum tumor endothelial marker1 as a potential biomarker for colorectal cancer diagnosis and cancer progression

Conditions: Colorectal Cancer

Summary: aim of work 1. measurement level of serumtem1 in crc patients by ng/ml using elisa kits . 2. find relation between serum tem1 level and staging of crc patients . 3. measurement of serum cea , ca19-9 levels by ng/ml so we can can compare their levels with serum tem1 level in crc patients .

colorectal cancer (crc) is a serious health problem, a challenge for research, and a model for studying the molecular mechanisms involved in its development. colorectal cancer is the third most common cancer in the world with approximately 1.4 million new cases and almost 700,000 associated deaths reported per year. the incidence, morbidity, and mortality rates of crc are expected to increase due to population aging and profound adverse effects of many life style-related factors. tumor growth is dependent on the complex and multistage angiogenesis. tumor blood vessels are characterized with abnormal morphology and function compared to normal blood vessels. except for disorganized structure, abnormal basement membrane, and increased leakiness, tumor vascular cells express unique protein named (tumor endothelial marker 1 (tem1)- endothialin-cd248) . tumor endothelial marker is a transmembrane glycoprotein which expression is significantly higher in tumor vasculature (5-,10-, and 20-fold) compared to the vessels of healthy tissues. it was suggested tems could discriminate between tumor and nontumor vascular cells. tissue overexpression of tem1 was found in patients with crc compared to healthy controls as well as in rectal cancer tissues when comparing tumor, lymph nodes, metastasis (tnm) stage i with other stages: tnm ii, iii, iv , although the biology of tem1 is intensely studied, including clinical studies with anti-tem1 molecules, only one study (2020) determined the potential usefulness of serum tem1 in crc. pietrzyk (2020) revealed that tem1 demonstrated higher levels in the serum of the patients with crc than healthy individuals and reported that tem1 could act as a potential diagnostic, progression, and prognostic serum biomarker for patients with crc. most commonly used serum markers for diagnosis and monitoring of crc are carcinoembryonic antigen (cea) and carbohydrate antigen 19-9 (ca 19-9). however, these markers show insufficient sensitivity, especially at early stages of crc. therefore, finding sensitive and specific, noninvasive, serum biomarkers is a prerequisite for early crc diagnosis.

Eligibility criteria:
inclusion criteria: 1-newly diagnosed crc patients. exclusion criteria: 1. chemotherapy 2. radiotherapy 3. surgical treatment 4. heart failure 5. angina 6. liver cirrhosis 7. renal cell carcinoma 8. gastric cancer.
fenofibrate in combination with ursodeoxycholic acid in primary biliary cirrhosis

Conditions: Primary Biliary Cirrhosis

Summary: ursodeoxycholic acid (udca) has been the only treatment for primary biliary cirrhosis (pbc) approved by us and european drug administrations. long-term use of udca(13-15 mg/kg/day) in patients with pbc improves serum liver biochemistries and survival free of liver transplantation however, about 40% of patients do not respond to udca optimally as assessed by known criteria for biochemical response. those patients represent the group in need for additional therapies, having increased risk of disease progression and decreased survival free of liver transplantation. both lab research and some clinical studies suggest that fenofibrate could improve cholestasis in multiple ways including reduce of bile acid synthesis, increase of biliary secretion and anti-inflammation effect. here we start a random, open and parallel clinical research to explore the effect of fenofibrate in the pbc treatment.


Eligibility criteria:
inclusion criteria: 1. signed informed consent 2. patient with pbc defined by 2 in 3 of the following criteria: a.positive antimitochondrial antibody type m2; b.abnormal serum alkaline phosphatases (alp \> 1,5n) and aminotransferase (ast/alt \> 1n) activities; c.histological hepatic injuries consistent with pbc. exclusion criteria: 1. pregnancy or desire of pregnancy. 2. breast-feeding. 3. co-existing liver diseases such as acute or chronic viral hepatitis, alcoholic liver disease, choledocholithiasis, autoimmune hepatitis, biopsy-proven non-alcoholic fatty liver disease, wilson's disease and hemochromatosis 4. history or presence of hepatic decompensation (e.g., variceal bleeds, encephalopathy, or poorly controlled ascites). 5. history of urolithiasis, nephritis or renal failure (clearance of creatinine \< 60 ml/mn). 6. hepatotoxic drugs use before recruiting. 7. fenofibrate anaphylaxis.

Keywords: pbc udca fenofibrate
comparing 61.2 gy radiotherapy dose versus 50.4 gy radiotherapy dose for locally advanced esophageal carcinoma

Conditions: Esophageal Squamous Cell Carcinoma

Summary: the purpose of this study is to determined the best definitive radiotherapy dosage for patients with locally advanced esophageal squamous cell carcinoma.


Eligibility criteria:
inclusion criteria: * joined the study voluntarily and signed informed consent form; * age 18-75 years; both genders * esophageal squamous cell carcinoma confirmed by pathology. * no radiotherapy, chemotherapy or other treatments prior to enrollment * locally advanced esophageal squamous cell carcinoma (t1n1-3m0, t2-4nxm0, txnxm1 (supraclavicular lymph node metastasis only) (ajcc 8th) * use of an effective contraceptive for adults to prevent pregnancy. * no severely abnormal hematopoietic, cardiac, pulmonary, renal, or hepatic function. no immunodeficiency. * wbc ≥ 3.5\*109/l, hemoglobin ≥ 9 g/dl, neutrophils ≥ 1·5\*109/l, platelet count ≥ 100\*109/l, alat and asat \< 2·5 \* uln, tbil \< 1·5 \* uln, and creatinine \< 1·5 \*uln. * ecog 0-2. * life expectancy of more than 3 months. * agreement of pet/ct accessment at 25-28 radiotherapy fraction. exclusion criteria: * total radiotherapy dose cannot reach 61.2gy/34fx in the condition of the nomal tissue dose complying to the standard criteria. * esophageal perforation, or hematemesis. * history of radiotherapy or chemotherapy for esophageal cancer. * history of surgery within 28 days before day 1. * history of prior malignancies (other than skin basal cell carcinoma or cervical carcinoma in situ with a disease-free survival of at least 3 years). * participation in other interventional clinical trials within 30 days. * pregnant or breast-feeding women or fertile patients who refused to use contraceptives. * drug addiction, alcoholism or aids. * uncontrolled seizures or psychiatric disorders. * any other condition which in the investigator's opinion would not make the patient a good candidate for the clinical trial.

Keywords: chemoradiotherapy esophageal cancer pet/ct
comparison of volume controlled ventilation with 1:1 inspiratory to expiratory ratio and autoflow-volume controlled ventilation in robot-assisted laparoscopic radical prostatectomy with steep trendelenburg position and pneumoperitoneum

Conditions: Robot Assisted Laparoscopic Prostatectomy

Summary: the purpose of this study is to compare the 1: 1 i: e ratio vcv and the autoflow vcv in patients undergoing robot assisted laparoscopic prostatectomy


Eligibility criteria:
inclusion criteria: 1. adult (20-80 years old) 2. patients undergoing robot assisted laparoscopic prostatectomy exclusion criteria: 1. history of copd 2. decreased heart function (ef \<50%) 3. bmi\>30 4. patients who cannot read the consent form (e.g., blind, foreigner)
stride study - a study in subjects with lopd who are currently being treated with ert

Conditions: Late-onset Pompe Disease

Summary: the purpose of the study is to evaluate changes in key clinical outcome measures (eg, motor, respiratory, fatigue) in adult subjects with late-onset pompe disease (lopd) subjects receiving standard-of-care enzyme replacement therapy (ert). additionally, information gained may be used in the design and conduct of future studies in lopd subjects.

the objective of this study is to evaluate the baseline characteristics and degree of change over time in clinical outcome measures commonly used to evaluate patients with lopd.

Eligibility criteria:
inclusion criteria: 1. subject has a diagnosis of pompe disease based on documented deficiency of gaa activity and a documented gaa mutation. 2. male and female subjects between 18 years and 75 years, inclusive and ≥ 50 kg. 3. subject must be currently receiving standard-of-care ert (alglucosidase alfa) at a dose of 20 mg/kg dose every other week. 4. subject must have been on ert for the preceding 2 years or more. 5. subject must have an upright forced vital capacity (fvc) within 35 to 90% of predicted normal (nhanes iii reference values), based on the higher of the screening or baseline value, if their 6 minute walk distance (6mwd) is \> 200 m. subject must have an upright fvc within 40 to 90% of predicted normal (nhanes iii reference values), based on the higher of the screening or baseline value, if their 6mwd is ≤ 200 m. if fvc is between 80 and 90% of predicted normal, the subject may enter the study if the percent predicted fvc value drops by 10% predicted or more in supine position 6. subject is able to walk at least 100 m in the 6mwt and the assessment is noted as valid. exclusion criteria: 1. subject has received any investigational therapy or pharmacological treatment for pompe disease, other than alglucosidase alfa within 30 days or 5 half lives, whichever is shorter, prior to the baseline visit or is anticipated to do so during the course of the study 2. subject is on any of the following prohibited medications within 30 days of baseline: * miglitol (eg, glyset) * miglustat (eg, zavesca) * acarbose (eg, precose, glucobay) * voglibose (eg, volix, vocarb, volibo) 3. subject requires use of invasive or non-invasive ventilatory support for \> 6 hours a day while awake. 4. subject has a medical or any other extenuating condition or circumstance that may, in the opinion of the investigator, pose an undue safety risk to the subject or compromise his/her ability to comply with protocol requirements. this includes clinical depression (as diagnosed by a psychiatrist or other mental health professional) with uncontrolled or poorly controlled symptoms. 5. subject is breastfeeding, or is pregnant or planning to become pregnant within the next 2 years. 6. other exclusion criteria according to the lumizyme/myozyme instructions for use.
evaluating the effects of cleansers on the skin

Conditions: Atopic Dermatitis

Summary: this will be a single visit study that will take approximately 2 hours. up to 50 subjects (up to 25 healthy subjects, and up to 25 subjects with ad) from bumc dermatology clinics will be enrolled in this study and randomized to receive the 7 cleansers on 7 test spots on their upper extremities. one spot will serve as a control and not receive any cleanser. each spot will be cleansed with the corresponding cleanser for 15 seconds then rinsed off with tap water. skin barrier will be measured at baseline, immediately after, 30, 60 and 90 minutes after rinse off.

up to 50 subjects (up to 25 with healthy skin or 25 with atopic dermatitis) meeting the inclusion criteria will be enrolled in this study. a physical exam will be performed to ensure the subjects have healthy skin versus atopic dermatitis. for atopic dermatitis subjects, ad severity will be graded by the easi score. site randomization will be performed to determine which cleansers will be used for each of the 8 test sites (one site will be randomized to act as a control and not receive any cleanser). baseline skin barrier function (tewl, ph and hydration) will be measured. then 1ml of each cleansers will be applied to the corresponding test sites, 2ml of tap water will be added, and lathered in a circular motion for 15 seconds. the sites will then be rinsed off with tap water for 15 seconds. arms will be padded dry. barrier functions will be measured again immediately after padding dry, and at 30, 60 and 90 minutes after.

Eligibility criteria:
inclusion criteria: male and female, at least 18 years of age subject must be able to comprehend and read the english language. healthy skin without concurrent atopic dermatitis or diagnosed with atopic dermatitis by a dermatologist exclusion criteria: subjects who do not fit the inclusion criteria. subjects unable to or unwilling to comply with the study procedures concurrently have other inflammatory skin conditions. prior known allergy to any components to of the cleansers tested a subject who, in the opinion of the investigator, will be uncooperative or unable to comply with study procedures. subject unable to speak or read the english language, since all consents and instructions will be provided in english. those that are prisoners or cognitively impaired
effect of extracorporeal shock waves on hypertrophy scar

Conditions: Hypertrophy; Scar

Summary: assess the effect of extracorporeal shock waves on hypertrophy scar

prolonged and abnormal scarring after trauma, burns and surgical procedures often results in functional and cosmetic deformities. a wide variety of treatments have been advocated for pathologic scars regression. unfortunately, the reported efficacy has been variable.unfocused extracorporeal shock wave therapy is a feasible and non-intensive treatment. and it is an emerging option for the treatment of painful and retracting scars. administration of eswt appears to result in significant improvements in scar clinical appearance, mobility and subjective pain. clinical data were mirrored by histologic changes in connective tissue appearance and scar vascularization. extracorporeal shock wave therapy is also an effective and conservative treatment for patients with aesthetic and functional sequela from burn scars. it is a feasible, cost-effective, well-tolerated treatment that can be used in the management of post-burn pathologic scars after the patients are briefed on the practical aspects of the treatment procedure.

Eligibility criteria:
inclusion criteria: 1. aged between 18 \~ 65 years old; 2. at least 4 weeks since onset of onset of wound; 3. healing wound with at least 6 scores in modified vancouver scar scale for more than four weeks 4. the most important of all, read and signed the inform concern of this study. exclusion criteria: 1. patients with open wound; 2. oxygen dependent 3. having evidence of cognitive deficit; 4. having local infection, severe inflammation or otherwise lesion that is not suggestive for eswt; 5. patient with serious medical problems, as uncontrolled hypertension, coagulopathy, recent severe hemorrhage, neoplasm, severe hepatic disease, epilepsy, cutaneous pathology, mental retardation.

Keywords: hypertrophy scar burn
adverse childhood experiences in substance-related disorders

Conditions: Alcohol Use Disorder; Trauma, Psychological

Summary: aversive childhood experiences (ace) and their relation to the development of an alcohol use disorder will be measured with fmri.

the aim of this study is to examine the impact of ace on stress sensitivity, cue-reactivity and emotion processing in individuals with aud. (neuro-) biological and physiological mechanisms underlying aud after ace will be studied. neural correlates of stress-sensitivity, emotion processing and alcohol cue-reactivity will be assessed using fmri. furthermore, blood and saliva samples will be used to assess biological and physiological mechanisms (e.g. salivary cortisol level or genetic markers of aud and possible gene-environment-interactions). the question whether individuals with aud and ace might tend to use alcohol to cope with stress, negative affect or intrusions (according to the self-medication model) will be explored. on the other hand, individuals with aud and low levels of ace might use alcohol for its positive effects (according to a positive reinforcement model). 90 individuals (30 hc and 60 individuals with aud and varying levels of ace) will be examined using interviews, questionnaires and fmri tasks as well as saliva and blood samples. all ethical votes and informed consents of participants are and will be obtained according to the declaration of helsinki.

Eligibility criteria:
inclusion criteria: * male and female * age between 18 and 65 * normal or correctable eyesight * sufficient ability to communicate with the investigators, to answer questions in oral and written form * "fully informed consent" * "written informed consent" * healthy individuals (audit score\<=8, alcohol intake \< 12g/ less than 5 days (women) \& 24g/ less than 5 days (men) * individuals with alcohol use disorder according to dsm-5 or 'heavy drinking' (alcohol intake \> 40g/ more than 5 days (women) \& 60g/ more than 5 days (men) with up to 28 days of abstinence and aversive childhood experiences exclusion criteria: * withdrawal of the declaration of consent * exclusion criteria for an mri scan (pregnancy, metal implants,...) * severe internal, neurological and psychiatric comorbidities * pharmacotherapy with psychoactive substances within the last 14 days (except treatment with ssri/snris for at least 28 days) * axis-i disorder according to icd-10 and dsm 5 (except tobacco and alcohol use disorder, substance abuse with less than 2(11) criteria according to dsm-5, mild depressive episode, adaptation disorder and specific phobia within the last 12 months) * positive urin drug screening (cannabis, amphetamine, opiates, benzodiazepines, cocaine) * withdrawal symptoms (ciwa-r \> 7) * intoxication at time of investigation (breathalyzer \> 0.3‰) * suicidal tendency or potential danger for others
a study to evaluate the efficacy of somatropin in adults with growth hormone deficiency caused by trauma and/or head injury

Conditions: Brain Injuries; Growth Hormone Deficiency Dwarfism

Summary: the purpose of this study is to assess the prevalence of ghd in patients who sustain a head injury or suffer a major traumatic event and to evaluate the efficacy of growth hormone (gh) therapy in the treatment of ghd caused by trauma or head injury

the study was terminated on october 9, 2003. the reason cited for the termination was due to poor patient recruitment and therefore not enough data could be collected to provide comprehensive analysis for reporting of results. no safety or efficacy issues were reported to cause the termination of the study.

Eligibility criteria:
inclusion criteria: * documented ghd * documented mild, moderate, and severe head injury (e.g.,glasgow coma scale score less than or equal to 15 or equivalent measure) exclusion criteria: * active systemic malignancy or active intracranial tumor * growth hormone replacement therapy in the last 12 months * history of dementia unrelated to traumatic brain injury
effect of robot-assisted training on foot drop in multiple sclerosis

Conditions: MS (Multiple Sclerosis)

Summary: the primary aim of this study is to: 1. collect pilot data on the effect of task-specific lower extremity training using the anklebot on subjects with multiple sclerosis (ms) and who have foot drop; 2. collect pilot data on the use of combination therapy on improving gait in subjects with ms. this therapy will use both anklebot training and robot-assisted gait training. hypothesis: both trainings will result in improved walking performance, but the combination therapy will result in greater gains than ankle training alone.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of ms by mcdonald criteria (mcdonald, compston et al. 2001). edss level between 3.5-5.5, who report ambulation problems. * presence of unilateral foot drop that is clinically apparent to the pi or pi designate. * must be able to ambulate 25 feet without an assisting device. exclusion criteria: * cardiovascular: recent mi \ 190/110 mmhg. * history of uncontrolled diabetes. * symptoms of orthostasis when standing up. * circulatory problems, history of vascular claudication or pitting edema. * unable to fully understand instructions in order to use the equipment or the process of the study. * body weight over 150 kg. * lower extremity injuries that limit range of motion or function. * joint problems (hip or leg) that limit range of motion or cause pain with movement despite treatment. * unstable fractures. * pressure sores with any skin breakdown in areas in contact with the body harness or lokomat apparatus. * chronic and ongoing alcohol or drug abuse. * pre-morbid, ongoing depression or psychosis. * ongoing physical therapy. * pregnancy (self-reported) * pi's determination of inability to complete the test protocol

Keywords: robot treadmill foot drop rehabilitation gait